Zelira Therapeutics (OTCQB: ZLDAF), a biopharmaceutical Company developing cannabinoid-based formulations for the treatment of a wide range of medical conditions, announced full enrollment in its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment for non-cancer pain. The study intends to evaluate the...
Baudax Bio (NASDAQ: BXRX), a pharmaceutical Company developing novel therapeutics for Acute Care Settings, announed the approval of a New Drug Application ( NDA) for ANJESO (meloxicam injection), intended for alleviating moderate to severe pain, either as a standalone treatment or in combination with other...
Enlivex Therapeutics (NASDAQ: ENLV), a Company focused on developing allogenic therapies for immune system rebalancing, announced positive interim efficacy data from its ongoing Phase Ib clinical trial in patients with severe sepsis. The analysis in based on data collated from 43 patients with severe sepsis,...
Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical Company, announced the withdrawal of its submission to the European Medicines Agency (EMA), for the grant of Marketing Authorization Application (MAA) for NUZYRA® (omadacycline). The Company was developing the candidate for two indications namely, acute bacterial skin and...
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019. The company’s stock rose by almost 32%, on the day it announced the news. It acts as a reversal agent for...
